Navigation Links
Monoclonal Antibody Reduces Exacerbations in Asthmatics

Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly// fewer disease exacerbations than individuals taking a placebo.

This research appears in the first issue for October 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Trevor T. Hansel, M.D., Ph.D., of the National Heart and Lung Institute at Royal Brompton Hospital in London, and 11 associates infused 14 patients with infliximab, a monoclonal antibody that binds and neutralizes tumor necrosis factor alpha (TNF?). Eighteen patients received placebo during the eight-week double-blind study.

According to the investigators, both structured and inflammatory cells in asthmatics can release TNF?, which is an intercellular messenger protein, a cytokine, produced by white blood cells.

“Anti-TNF? therapy has been shown to be effective in patients with rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and psoriasis, but ineffective in patients with chronic obstructive pulmonary disease (COPD),” said Dr. Hansel. “Preliminary reports of efficacy in asthma patients with concomitant rheumatoid arthritis have been encouraging. Small prospective studies of a soluble receptor directed against TNF? in severe refractory asthma have also shown improvements in lung function and airway hyperresponsiveness.”

During the study, 13 of the 18 patients on placebo (72 percent) experienced exacerbations, as compared to only four out of 14 patients (29 percent) on infliximab therapy.

All patients in the study cohort continued to use inhaled corticosteroids for their asthma. Study protocol required them to be symptomatic during a two- to four-week run-in period.

After the run-in phase, infusions of either infliximab or placebo were administered at weeks zero, two and six.

“Treatment with infliximab reduced the number of moderate exacerbations in patients with asthma, as monitored by morning and evening use of an electronic spirometer incorporating a clinical diary,” said Dr. Hansel. “Although infliximab therapy did not show significant efficacy for the primary endpoint of monitoring peak expiratory flow (PEF), it did produce a significant decrease in the diurnal (during the day) variation in the PEF rate.”

(With PEF monitoring, patients take as deep as a breath as possible, then exhale as forcefully as possible into the mouthpiece of the PEF meter for three tests. As a gauge for pulmonary function, it is especially useful in patients older than age five who have persistent moderate to severe asthma.)

“None of the exacerbations we saw in our study warranted treatment with oral corticosteroids or hospitalization, so they cannot be considered to have been severe,” said Dr. Hansel.

The researchers noted there were no adverse events associated with using the monoclonal antibody for treatment.

“Given that infliximab therapy was well-tolerated and appeared to reduce the incidence of asthma exacerbations, anti-TNF? therapy merits further study in larger clinical trials in patients with severe asthma,” concluded Dr. Hansel.


Related medicine news :

1. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
2. Monoclonal antibodies show promise in treatment of blood cancer
3. Monoclonal Anti-Body To Revolutionize Brain Cancer Treatment
4. Monoclonal Antibody based system for Anthrax detection
5. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
6. Human Antibody That Can Block SARS
7. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
8. Cuba Registers New Antibody
9. Single Sugar Enables Antibody to Treat Inflammation
10. Monoclonal Antibody based system for Anthrax detection
11. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
Post Your Comments:

(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy Corp. Congress and ... developer of renewable energy technologies capable of producing commercially useful amounts of thermal ... its WET™ and HHT™ Boiler System reactor core modules were presented to Congress ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital – ... Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid or ... care services available to its members to help them make informed decisions about ...
(Date:11/24/2015)... ... 2015 , ... Bibliomotion is thrilled to announce the launch of ... Diversity by Nancy M. Schlichting, Chief Executive Officer of Henry Ford Health ... the needs of patients and their families, shaped my desire to improve the system ...
(Date:11/24/2015)... Nashville, Tennessee (PRWEB) , ... November 24, 2015 , ... ... 2015-2016 Pharmacy Quality Trend Report . Throughout the past year there have been multiple ... more mature state. During this transition, PharmMD has enabled their customers and partners to ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Enova Illumination is pleased to announce ... Helsinki, Finland to combine their world class ... cutting edge of medical visualization: Enova is the first ... United States and Novocam is the manufacturer ... the world,s most powerful battery-operated LED headlight with high-quality ...
(Date:11/24/2015)... 24, 2015  BioPlast Manufacturing, a manufacturer of ... clinical diagnostic and biotech environments, announced today that ... quality petri dishes. This acquisition is aligned with ... of products that are designed and tested by ... quality.  Bristol, Pennsylvania ...
(Date:11/24/2015)... 2015  Eyewear brand Revo has debuted a ... singer and activist Bono as part of the " Buy ... blindness in more than 5 million people by 2020.  ... $10 from the sale of every pair of Revo sunglasses, ... of $10 million to the "Buy Vision, Give Sight" initiative. ...
Breaking Medicine Technology: